VERV News

The IPO market was in full swing this past week as 16 IPOs and six SPACs went public. The IPO pipeline cooled down with just one IPO and nine SPACs submitting initial filings. The largest deal of the week, Lyell Immunopharma (LYEL) priced at the midpoint to raise $425 million at a $4.7 billion market cap. The company is using proprietary genetic and...read more

Verve Therapeutics, a preclinical biotech developing single-course gene editing therapies for cardiovascular disease, raised $267 million by offering 14 million shares at $19, above the range of $16 to $18. The company offered 2.2 million more shares than anticipated. Insiders Wellington Management and Casdin Capital and new investor Fidelity had indicated on up to an aggregate of...read more

Verve Therapeutics, a preclinical biotech developing single-course gene editing therapies for cardiovascular disease, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $201 million by offering 11.8 million shares at a price range of $16 to $18. Insiders Wellington Management and Casdin Capital and new investor Fidelity have indicated an...read more

Updated Monday, 6/14. 15 IPOs are currently slated to raise $2.5 billion in the week ahead, led by a preclinical biotech being valued at $4.7 billion. The largest deal of the week, Lyell Immunopharma (LYEL) plans to raise $425 million at a $4.7 billion market cap. The company is using proprietary genetic and epigenetic reprogramming to develop T...read more